Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited
Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited
复制标题
DOI：
10.1097/00126334-200304010-00017
复制
发表时间：
2003-04-01
影响因子：
3.6
通讯作者：
Phillips, AN
中科院分区：
文献类型：
--
作者：
Moore, AL;Kirk, O;Phillips, AN
背景：高效抗逆转录病毒疗法(HAART)显著改善了HIV感染者的预后。关于HAART后潜在的性别影响患者预后的争论仍在继续。方法：患者来自EuroSIDA队列，天真地使用蛋白酶抑制剂和非核苷类逆转录酶抑制剂，并且在开始HAART之前至少有一次病毒载量和CD4测量。终点是病毒学(达到500拷贝/毫升的时间)、免疫学(CD4细胞计数上升到100/mm的时间)和临床(新发艾滋病和死亡的时间)。用COX回归模型得出的风险比(HR)比较了女性和男性达到终点的比率。结果：在2547名患者中，20%(511)为女性。非白人女性明显多于男性(24%比10%，p
Background: Highly active antiretroviral therapy (HAART) has dramatically improved the prognosis for patients with HIV. There is ongoing debate over a potential gender effect on patient outcome after HAART.Methods: Individuals were from the EuroSIDA cohort, naive to protease inhibitors and nonnucleoside reverse transcriptase inhibitors, and had at least one viral load and CD4 measurement prior to starting HAART. Endpoints were virologic (time to 500 copies/mL]), immunologic (time to a 100/mm cell rise in CD4 count) and clinical (time to new AIDS and death).Hazard ratios (HR), derived using Cox regression models, compared female to male rates of achieving endpoints.Results: Of 2547 patients, 20% (511) were female. Significantly more females than males were nonwhite (24% vs. 10%, p